Alectinib approved by FDA for ALK-Positive NSCLC

Farydak (panobinostat) now FDA-approved for multiple myeloma
Farydak (panobinostat) now FDA-approved for multiple myeloma

(HealthDay News) -- Alecensa (alectinib) has been approved by the U.S. Food and Drug administration to treat anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer, the agency said Friday in a news release.

Alecensa is designed to block the effects of the ALK protein, thereby preventing these cancer cells from growing and spreading. The pill is sanctioned for instances of worsening disease after treatment with Xalkori (crizotinib), or if they are unable to tolerate Xalkori.

The most common side effects of the drug are fatigue, constipation, edema, and myalgia. More serious side effects could include liver problems, life-threatening lung inflammation, very slow heart rate, and severe muscle problems. Users also may be prone to more easily becoming sunburned.

"Today's approval provides a new therapy for a group of patients who would have few treatment options once their disease no longer responds to treatment with Xalkori," Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research, said in a statement. "In addition to the primary effect on tumors in the lung, Alecensa clinical trials provide evidence of an effect on tumors that had spread to the brain, which is an important effect for clinicians to understand."

Alecensa is marketed by San Francisco-based Genentech.

More Information

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs